Literature DB >> 9456497

Low-molecular-weight heparin and abciximab for thrombo-occlusive saphenous vein graft disease. Report of 2 cases.

R Yaryura1, J Doucet, V S Mathur.   

Abstract

Both reoperation and alternative treatments for thrombo-occlusive disease of saphenous vein grafts have been fraught with a high rate of complications and a low rate of long-term success. We report 2 cases in which thrombo-occlusive saphenous vein graft disease was treated with the aid of abciximab during the intervention and with low-molecular-weight heparin for 7 to 12 days in an outpatient setting.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9456497      PMCID： PMC325487     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN： 0730-2347


  10 in total

1.  Percutaneous transluminal angioplasty of a totally occluded venous bypass graft: a challenge that should be resisted.

Authors:  P J de Feyter; P Serruys; M van den Brand; H Meester; K Beatt; H Suryapranata
Journal:  Am J Cardiol       Date:  1989-07-01       Impact factor: 2.778

Review 2.  Low molecular weight heparin.

Authors:  J Hirsh; M N Levine
Journal:  Blood       Date:  1992-01-01       Impact factor: 22.113

3.  The spectrum of pathologic changes in aortocoronary saphenous vein grafts.

Authors:  G E Batayias; J J Barboriak; M E Korns; K Pintar
Journal:  Circulation       Date:  1977-09       Impact factor: 29.690

4.  Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.

Authors:  H K Gold; H D Garabedian; R E Dinsmore; L J Guerrero; J E Cigarroa; I F Palacios; R C Leinbach
Journal:  Circulation       Date:  1997-04-01       Impact factor: 29.690

5.  Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts.

Authors:  B W Lytle; F D Loop; D M Cosgrove; N B Ratliff; K Easley; P C Taylor
Journal:  J Thorac Cardiovasc Surg       Date:  1985-02       Impact factor: 5.209

6.  Transcatheter therapy of thrombotic-occlusive lesions in saphenous vein grafts.

Authors:  F A Ceceña; D H Hoelzinger
Journal:  Am J Cardiol       Date:  1996-07-01       Impact factor: 2.778

7.  Accelerated "atherosclerosis". A morphologic study of 97 saphenous vein coronary artery bypass grafts.

Authors:  B H Bulkley; G M Hutchins
Journal:  Circulation       Date:  1977-01       Impact factor: 29.690

8.  Safety and efficacy of extended urokinase infusion plus stent deployment for treatment of obstructed, older saphenous vein grafts.

Authors:  S J Denardo; N B Morris; K J Rocha-Singh; G P Curtis; D S Rubenson; P S Teirstein
Journal:  Am J Cardiol       Date:  1995-10-15       Impact factor: 2.778

9.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

Authors:  M Levine; M Gent; J Hirsh; J Leclerc; D Anderson; J Weitz; J Ginsberg; A G Turpie; C Demers; M Kovacs
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

10.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.